Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 05, 2020 07:00 ET | Source: Cyclacel

Cyclacel Pharmaceuticals to Release Second Quarter 2020 Financial Results

BERKELEY HEIGHTS, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
July 13, 2020 07:00 ET | Source: Cyclacel

Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer

-- Characterization of fadraciclib published in peer-reviewed journal shows specificity against CDK2 and CDK9 and enablement of apoptosis of cancer cells driven by MCL1, cyclin E and/or MYC – ...
May 12, 2020 16:05 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Reports First Quarter 2020 Financial Results

- Conference Call Scheduled May 12, 2020 at 4:30 p.m. ET - - Following Recent Financing Cash Runway to End of 2022 - BERKELEY HEIGHTS, N.J., May 12, 2020 (GLOBE NEWSWIRE) -- Cyclacel...
May 05, 2020 07:00 ET | Source: Cyclacel

Cyclacel Pharmaceuticals to Release First Quarter 2020 Financial Results

BERKELEY HEIGHTS, N.J., May 05, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
April 24, 2020 16:05 ET | Source: Cyclacel

Cyclacel Announces Closing of $20 Million Public Offering

BERKELEY HEIGHTS, N.J., April 24, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing...
April 21, 2020 08:27 ET | Source: Cyclacel

CYCLACEL ANNOUNCES PRICING OF $20 MILLION PUBLIC OFFERING

BERKELEY HEIGHTS, N.J., April 21, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing...
April 20, 2020 07:00 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Announces Collaboration With the University of Edinburgh to Study Its CDK Inhibitors to Reduce Runaway Inflammation in COVID-19 Disease

BERKELEY HEIGHTS, N.J. and DUNDEE, United Kingdom, April 20, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") a biopharmaceutical...
April 14, 2020 12:30 ET | Source: Cyclacel

Cyclacel Announces Reverse Stock Split

BERKELEY HEIGHTS, N.J., April 14, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing...
February 26, 2020 16:05 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

– Anticancer Activity of Fadraciclib (CYC065) Monotherapy in Patients with MCL1 Amplified Solid Tumor and Fadraciclib-venetoclax Combination in Patients with Relapsed or Refractory AML/MDS and CLL – ...
February 19, 2020 07:00 ET | Source: Cyclacel

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2019 Financial Results

BERKELEY HEIGHTS, N.J., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...